Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O00212
UPID:
RHOD_HUMAN
Alternative names:
Rho-related protein HP1
Alternative UPACC:
O00212
Background:
Rho-related GTP-binding protein RhoD, also known as Rho-related protein HP1, plays a pivotal role in endosome dynamics, coordinating membrane transport with cytoskeleton function. It is crucial in the internalization and trafficking of activated tyrosine kinase receptors like PDGFRB and is involved in actin cytoskeleton reorganization, impacting filopodia formation and actin filament bundling.
Therapeutic significance:
Understanding the role of Rho-related GTP-binding protein RhoD could open doors to potential therapeutic strategies.